bioAffinity Technologies Presents its Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

PUBLISHED ON December 6, 2021

December 6, 2021 (San Antonio, TX) bioAffinity Vice President of Research David Elzi, Ph.D., will discuss how bioAffinity successfully uses RNA interference to knock down expression of two genes that results in killing cancer cells with little or no effect on normal cells at Cell Bio, a joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), held virtually Dec. 6-11, 2021.

bioAffinity Technologies Announces Xavier T. Reveles Promoted to Vice President of Operations

PUBLISHED ON October 14, 2021

October 14, 2021 (San Antonio, TX) bioAffinity Technologies today announced that Xavier T. Reveles, MS, CG, has been promoted to Vice President of Operations. Reveles will be responsible for overseeing the commercialization of the Company’s diagnostic products, including CyPath® Lung, a highly accurate, non-invasive test to diagnose early-stage lung cancer.

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

PUBLISHED ON September 23, 2021

September 23, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced that the Australian Patent Office issued a Notice of Acceptance for bioAffinity subsidiary OncoSelect’s patent protecting compositions and methods to treat cancer using chemotherapeutic agents conjugated to porphyrins, resulting in targeted delivery of the drugs.

San Antonio-based bioAffinity Technologies’ first cancer test ready to hit the market

PUBLISHED ON September 16, 2021

San Antonio Business Journal (September 16, 2021) More than seven years after its launch, bioAffinity Technologies is on the cusp of commercializing its initial product, the CyPath^® Lung cancer diagnostic test. Precision Pathology Services, which has licensed the San Antonio-based company’s technology, has completed its validation of the clinical performance of CyPath^® Lung and is now preparing to take the non-invasive test to market.

bioAffinity Technologies Announces Precision Pathology Services’ Validation of Novel Non-Invasive Early Lung Cancer Test

PUBLISHED ON September 14, 2021

September 9, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company advancing innovative cancer diagnostics, announced that Precision Pathology Services, a CAP/CLIA-certified anatomic and clinical pathology laboratory, has fully validated the clinical performance of CyPath® Lung, a non-invasive flow cytometric test for early-stage lung cancer.